Medica Jadertina, Vol. 41 No. 3-4, 2011.
Izvorni znanstveni članak
Pegylated interferon alfa 2a (Pegasys) plus ribavirin versus interferon alfa 2a (Roferon-A) plus ribavirin in the treatment of chronic hepatitis C
Dražen Zekanović
; Opća bolnica Zadar, Odjel za interne bolesti
Boris Dželalija
; Opća bolnica Zadar, Odjel za suzbijanje i liječenje zaraznih bolesti
Sanda Goll-Barić
; Roche d.o.o. Osijek
Alan Medić
; Zavod za javno zdravstvo Zadarske županije, Služba za epidemiologiju, Zadar
Sažetak
The aim of this study was to determine the efficiency and safety of PEG interferon alfa 2a therapy in combination with ribavirin versus interferon alfa 2a therapy plus ribavirin (double therapy) for 48 weeks
among chronic hepatitis C patients who were unsuccessfully treated with interferon alfa 2a or alfa 2b (monotherapy).
Methods. There were two groups of patients. In group A there were 25 patients in the period from 2003 to 2005 who were given alfa 2a (Roferon A) in doses of 6 MIU three times a week together with ribavirin 1000 mg or 1200 mg daily for a period of 48 weeks. In group B there were 25 patients in the period from 2005 to 2008 who were given pegylated interferon alfa 2a (Pegasys) in weekly doses of 180 mg together with ribavirin of 1000 or 1200 mg for a period of 48 weeks.
Results. The sustained viral response (SVR) in group A was 16% versus 24% in group B. SVR was statistically significantly higher in the group of patients infected with HCV genotypes 2 and 3 in comparison to genotype 1 (in group A 50% vs 5% and in group B 57% vs 11%). Both groups of patients had side effects that varied from mild to moderate, so that it was not necessary to lower the medicine doses or to stop with the therapy temporarily. All side effects disappeared when the treatment ended.
Conclusion. Double therapy with PEG interferon alfa and ribavirin is more efficient than the double therapy with conventional interferon and Ribavirin in the treatment of chronic hepatitis C patients who did
not respond to the monotherapy with conventional interferon.
Ključne riječi
Chronic hepatitis C; non response; peginterferon alfa-2a
Hrčak ID:
77252
URI
Datum izdavanja:
1.2.2012.
Posjeta: 2.839 *